Skip to main content
Log in

Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus

Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objectives

To determine if the past presence of anti-double-strand (ds)DNA antibody (Ab) will predict subsequent disease activity in patients with systemic lupus erythematosus (SLE).

Methods

A longitudinal study of clinical and serological disease manifestations registered during 2,412 patient months of follow-up in a well-defined lupus cohort. Organ-specific disease manifestations, the modified SLE disease activity index (M-SLEDAI) score, disease flares (M-SLEDAI increase ≥3) and predictive value of anti-dsDNA Ab testing [by enzyme-linked immunoabsorbent assay (ELISA) and Crithidia luciliae immunofluorescence (CLIFT) assays] were related to past anti-dsDNA Ab status.

Results

Anti-dsDNA Ab was previously demonstrated in 54 (57%) patients (group 1), while they were not earlier detected in 40 (43%) patients (group 2). The number of patients experiencing flares (46 vs 25%, p<0.01), the total number of flares (75 vs 17, p<0,001) as well as overall (60 vs 24 per 100 patient years, p<0,001) and organ-specific flare rate were higher in group 1. After adjustment for control frequency, group 1 remained at a higher risk for renal flares [odds ratio (OR) 2.4; confidence interval (CI) 1.5–4.1], and group 2 was at a higher risk for skin flares (OR 0.7; CI 0.5–0.8). While anti-dsDNA Ab testing overall was performed slightly more often in group 1 (OR 1.45; CI 1.0–4.6), anti-dsDNA Ab testing during flares was similar in both groups.

Conclusion

The past presence of anti-dsDNA Ab identified patients with an increased risk of subsequent renal flares. However, as a new onset of anti-dsDNA Abs occurred late in the disease course, prior anti-dsDNA status was not adequate to predict disease flares.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277

    Article  PubMed  CAS  Google Scholar 

  2. Hahn BH (1998) Antibodies to DNA. N Engl J Med 338(19):1359–1368

    Article  PubMed  CAS  Google Scholar 

  3. Pisetsky DS (1998) Anti-DNA antibodies in systemic lupus erythematosus: a case of mistaken identity? J Rheumatol 25(2):195–197

    PubMed  CAS  Google Scholar 

  4. Rekvig OP, Andreassen K, Moens U (1998) Antibodies to DNA—towards an understanding of their origin and pathophysiological impact in systemic lupus erythematosus. Scand J Rheumatol 27(1):1–6

    Article  PubMed  CAS  Google Scholar 

  5. Isenberg DA, Ravirajan CT, Rahman A, Kalsi J (1997) The role of antibodies to DNA in systemic lupus erythematosus—a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus 6(3):290–304

    Article  PubMed  CAS  Google Scholar 

  6. Rekvig OP, Nossent JC (2003) Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum 48(2):300–312

    Article  PubMed  CAS  Google Scholar 

  7. Ho A, Magder LS, Barr SG, Petri M (2001) Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2342–2349

    Article  PubMed  CAS  Google Scholar 

  8. Ho A, Barr SG, Magder LS, Petri M (2001) A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2350–2357

    Article  PubMed  CAS  Google Scholar 

  9. Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE (1979) Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 22(3):226–235

    Article  PubMed  CAS  Google Scholar 

  10. Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45(5):359–366

    PubMed  CAS  Google Scholar 

  11. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33(5):634–643

    Article  PubMed  Google Scholar 

  12. Bootsma H, Spronk PE, ter Borg EJ, Hummel EJ, de Boer G, Limburg PC et al (1997) The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 56(11):661–666

    Article  PubMed  CAS  Google Scholar 

  13. Williams RC Jr, Malone C, Blood B, Silvestris F (1999) Anti-DNA and anti-nucleosome antibody affinity—a mirror image of lupus nephritis? J Rheumatol 26(2):331–346

    PubMed  CAS  Google Scholar 

  14. Zonana-Nacach A, Roseman JM, McGwin G Jr, Friedman AW, Baethge BA, Reveille JD et al (2000) Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Lupus 9(2):101–109

    Article  PubMed  CAS  Google Scholar 

  15. Kavanaugh A (2001) The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum 44(10):2221–2223

    Article  PubMed  CAS  Google Scholar 

  16. Kavanaugh AF, Solomon DH (2002) Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 47(5):546–555

    Article  PubMed  CAS  Google Scholar 

  17. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE (1996) Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 23(11):1891–1896

    PubMed  CAS  Google Scholar 

  18. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D (1996) Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 39(3):370–378

    Article  PubMed  CAS  Google Scholar 

  19. Rauch J, Hazeltine M, Tannenbaum H, Danoff D, Isenberg DA, Wild J et al (1990) Association of anti-DNA idiotype markers with clinical and serological manifestations in patients with systemic lupus erythematosus. J Rheumatol 17(2):178–185

    PubMed  CAS  Google Scholar 

  20. Nossent HC (2001) Systemic lupus erythematosus in the Arctic region of Norway. J Rheumatol 28(3):539–546

    PubMed  CAS  Google Scholar 

  21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640

    Article  PubMed  CAS  Google Scholar 

  22. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1994) Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 21(8):1468–1471

    PubMed  CAS  Google Scholar 

  23. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1992) Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 19(4):608–611

    PubMed  CAS  Google Scholar 

  24. Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP (2004) Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 63(4):386–394

    Article  PubMed  CAS  Google Scholar 

  25. Olaussen E, Rekvig OP (1999) Screening tests for antinuclear antibodies (ANA): selective use of central nuclear antigens as a rational basis for screening by ELISA. J Autoimmun 13(1):95–102

    Article  PubMed  CAS  Google Scholar 

  26. Aarden LA, de Groot ER, Feltkamp TE (1975) Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 254:505–515

    Article  PubMed  CAS  Google Scholar 

  27. Spronk PE, Bootsma H, Kallenberg CG (1998) Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment? Clin Rev Allergy Immunol 16(3):211–218

    Article  PubMed  CAS  Google Scholar 

  28. Swaak AJ, Nossent JC, Smeenk RJ (1991) Prognostic factors in systemic lupus erythematosus. Rheumatol Int 11(3):127–132

    Article  PubMed  CAS  Google Scholar 

  29. Petri M (1995) Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 7(5):395–401

    Article  PubMed  CAS  Google Scholar 

  30. Petri M, Barr SG, Zonana-Nach A, Magder L (1999) Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. J Rheumatol 26(2):502–503

    PubMed  CAS  Google Scholar 

  31. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J et al (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345(8965):1595–1599

    Article  PubMed  CAS  Google Scholar 

  32. Arce-Salinas A, Cardiel MH, Guzman J, Alcocer-Varela J (1996) Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 23(5):846–849

    PubMed  CAS  Google Scholar 

  33. FitzGerald JD, Grossman JM (1999) Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 8(8):638–644

    Article  PubMed  CAS  Google Scholar 

  34. Barr SG, Zonana-Nacach A, Magder LS, Petri M (1999) Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 42(12):2682–2688

    Article  PubMed  CAS  Google Scholar 

  35. Wluka AE, Liang MH, Partridge AJ, Fossel AH, Wright EA, Lew RA et al (1997) Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. Arthritis Rheum 40(1):57–61

    Article  PubMed  CAS  Google Scholar 

  36. Haga HJ, Brun JG, Rekvig OP, Wetterberg L (1999) Seasonal variations in activity of systemic lupus erythematosus in a subarctic region. Lupus 8(4):269–273

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This study was supported by grants from Helse Nord and Tromsø Reumatiker Forening.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hans Nossent.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van den Berg, L., Nossent, H. & Rekvig, O. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol 25, 347–352 (2006). https://doi.org/10.1007/s10067-005-0047-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-005-0047-7

Keywords

Navigation